Exploring on the Hyperinsulinism Management in Women with Polycystic Ovary Syndrome

This comprehensive review focuses on the relevance of hyperinsulinemia in women with polycystic ovary syndrome (PCOS). It highlights the most robust scientific evidence on the management of this condition within the context of PCOS. A systematic search of studies published in English language was conducted using Google Scholar, PubMed, and Cochrane databases. Keywords used alone or combined with “PCOS” included: hyperinsulinemia, incretin hormones, and dipeptidyl peptidase-4. The search strategy was complemented by manual review of references from selected articles. Glucagon-like peptide-1 receptor agonist and glucagon-dependent insulin tropic polypeptide provide various metabolic beneficial effects in addition to the weight loss. Dipeptidyl peptidase-4 inhibitors, expressed by various cells, prevent GLP-1 degradation and decreases insulin signaling in different cells, particularly in hepatocytes, and adipocytes. Regarding the management of hyperinsulinemia, the review suggests that incretin hormone agonist and dipeptidyl peptidase-4 inhibitors may represent favorable therapeutic options for addressing insulin resistance in women with PCOS, particularly those with obesity. However, this review does not explore dietary interventions and physical activity as primary strategies for managing dysglycemia in this population.